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The three treatments showed similar results in terms of the clinical outcomes. Both ALIF/TFC (anterior lumbar interbody fusion using Ray threaded fusion cages) and PLIF/TFC (posterior lumbar interbody fusion with Ray threaded fusion cages) were significantly less costly than PLIF/Plate (posterior lumbar interbody fusion with concomitant posterior stabilisation). Consequently, PLIF/Plate cannot be considered a cost-effective strategy for patients with lowerback pain (from a fiscal point of view).
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparator was clear. In the USA there is still a debate on which interbody technique should be preferred for patients suffering from lower-back pain, therefore the authors compared three procedures currently in use. You should decide whether they are valid comparators in your own setting
Validity of estimate of measure of effectiveness
The effectiveness analysis used a cohort study. This can present some limitations in terms of the internal validity of the results. However, the authors performed several statistical analyses to assure the comparability of the three groups. The main limitation of the effectiveness analysis appears to have been the small sample size, which may have created problems in detecting statistically significant differences in the results. The clinical outcomes were based on patientreported health states, which is appropriate for the type of disease. The study sample appears to have been representative of the study population.
Validity of estimate of measure of benefit
No summary benefit measure was used in the economic analysis. Given that the results obtained in the clinical outcomes among the three procedures were not statistically significantly different, the study was categorised as a CMA.
Validity of estimate of costs
All the categories of costs relevant to the perspective of the analysis were included. The authors performed statistical analyses to investigate the significance of the difference in the costs. No details were given on the unit costs and only the total costs were reported. No sensitivity analyses were performed, thus reducing the transferability of the results. The cost estimates were specific to the study setting.
Other issues
The authors compared the results of their study, in terms of the clinical outcomes, with those found in published literature. However, no comparison was made on the cost side. In addition, the lack of sensitivity analyses limits the generalisability of the results. The authors' conclusions were drawn on the basis of there being no significant difference in the effectiveness results among the three treatments. However, this could have been due more to the small sample size than to a real similarity in the results. In fact, there was an evident trend in favour of PLIF/TFC and PLIF/Plate in the majority of the clinical outcomes.
Implications of the study
The results of this study suggested that, compared with PLIF/Plate, ALIC/TFC and PLIF/TFC should be considered as the most cost-effective strategies for patients with lower-back pain. However, further studies should be performed to confirm these results, possibly with a different study design (randomised clinical trial) and larger sample size.
